Compare · head to head
Astellas Pharma vs HUTCHMED (China)
Astellas Pharma ranks higher overall — 360 rank 100 vs 27.
Astellas Pharma leads on Value (85 vs 54), Quality (75 vs 42), Growth (62 vs 41), Safety (66 vs 44) and Sentiment (50 vs 44).
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | Japan | Hong Kong SAR China |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | X-Large | Medium |
| ISIN | JP3942400007 | KYG4672N1198 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 100 | 27 |
| Value | 85 | 54 |
| Quality | 75 | 42 |
| Growth | 62 | 41 |
| Safety | 66 | 44 |
| Sentiment | 50 | 44 |
| Quality details | ||
| Profitability | 69 | 48 |
| Cash Truth | 81 | 36 |
Astellas Pharma vs Yuyu PharmaAstellas Pharma vs WuXi Biologics (Cayman)Astellas Pharma vs Whanin PharmAstellas Pharma vs Sino BiopharmaceuticalAdd a third stock →
Full analyses: Astellas Pharma · HUTCHMED (China)
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100